Condensed Consolidated Statements of Loss and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue
Research and development collaborations (note 9)	$ 1,916	$ 644
Operating expenses:
Research and development	62,510	44,283
General and administrative	12,092	1,296
Total operating expenses	74,602	45,579
Loss from operations	(72,686)	(44,935)
Other income (expense):
Interest income	302	741
Other (expense) income, net (note 10)	(315)	129
Total other income (expense), net	(13)	870
Loss before income taxes	(72,699)	(44,065)
Income tax recovery (expense)	74	(525)
Net loss and comprehensive loss	(72,625)	(44,590)
Net loss and comprehensive loss	$ (72,625)	$ (44,590)
Net loss per common share (note 4):
Basic (in dollars per share)	$ (1.18)	$ (0.87)
Diluted (in dollars per share)	$ (1.19)	$ (0.87)
Weighted-average common shares outstanding (note 4):
Basic (in shares)	61,367,368	51,367,663
Diluted (in shares)	61,378,170	51,367,663